{
    "clinical_study": {
        "@rank": "110757", 
        "arm_group": {
            "arm_group_label": "ARQ 197", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of ARQ 197 in\n      hepatocellular carcinoma (HCC) patients treated with daily oral ARQ 197, to determine the\n      recommended dose of ARQ 197 in advanced HCC patients."
        }, 
        "brief_title": "Study of ARQ 197 in Hepatocellular Carcinoma (HCC)", 
        "condition": "Advanced Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed HCC patients who are resistant to, intolerable to, or rejecting a systemic\n             sorafenib therapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Child-Pugh classification A at the time of registration\n\n          -  Adequate bone marrow, liver, and renal functions within 14 days prior to registration\n\n        Exclusion Criteria:\n\n          -  Prior therapy with a c-Met inhibitor (including ARQ 197)\n\n          -  Any systemic anti-tumor treatment or investigational agent within 2 weeks prior to\n             registration. If the treatment/agent was antibody, within 4 weeks\n\n          -  Local treatment for malignancy within 4 weeks prior to registration\n\n          -  Major surgical procedure within 4 weeks prior to registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656265", 
            "org_study_id": "ARQ 197-008"
        }, 
        "intervention": {
            "arm_group_label": "ARQ 197", 
            "description": "Daily repeating dose of oral ARQ 197, twice a day just after meals.  Dose of ARQ 197 will be escalated according to 3+3 rule.", 
            "intervention_name": "ARQ 197", 
            "intervention_type": "Drug", 
            "other_name": "Tivantinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kashiwa-city", 
                    "country": "Japan", 
                    "state": "Chiba"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Adverse Event collection and assessment will be done for all treated subjects to assess the safety, tolerability.  The grading for the severity of the adverse events will be determined according to CTCAE ver 4.0.", 
            "measure": "Number of participants with dose-limiting toxicity (DLT), as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "DLT observation period will be the first 28 days after the start of ARQ 197 treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "maximum concentration (Cmax), area under the curve (AUC), half-life (t1/2), apparent clearance (Cl/F), and apparent volume of distribution in the terminal elimination phase (Vz/F).", 
                "measure": "Profiles of Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Plasma sample correction at pre-dose 1, 2, 4, 6, 10, 12 and 24 hours on day 1; at pre-dose, 1, 2, 4, 6, 10, 12 hours on day 15; and at pre-dose on day 29."
            }, 
            {
                "measure": "Antitumor effects according to RECIST 1.1.", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks"
            }
        ], 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}